[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse BATF

Summary
SymbolBATF
Namebasic leucine zipper transcription factor, ATF-like
Aliases SFA-2; BATF1; activating transcription factor B; SF-HT-activated gene 2; B-ATF1; SFA2; B-cell-activating tra ......
Chromosomal Location14q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Note=Present in the nucleus and cytoplasm, but shows increased nuclear translocation after activation of T-cells.
Domain PF00170 bZIP transcription factor
Function

AP-1 family transcription factor that controls the differentiation of lineage-specific cells in the immune system: specifically mediates the differentiation of T-helper 17 cells (Th17), follicular T-helper cells (TfH), CD8(+) dendritic cells and class-switch recombination (CSR) in B-cells. Acts via the formation of a heterodimer with JUNB that recognizes and binds DNA sequence 5'-TGA[CG]TCA-3'. The BATF-JUNB heterodimer also forms a complex with IRF4 (or IRF8) in immune cells, leading to recognition of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific regulatory element, followed by cooperative binding of BATF and IRF4 (or IRF8) and activation of genes. Controls differentiation of T-helper cells producing interleukin-17 (Th17 cells) by binding to Th17-associated gene promoters: regulates expression of the transcription factor RORC itself and RORC target genes such as IL17 (IL17A or IL17B). Also involved in differentiation of follicular T-helper cells (TfH) by directing expression of BCL6 and MAF. In B-cells, involved in class-switch recombination (CSR) by controlling the expression of both AICDA and of germline transcripts of the intervening heavy-chain region and constant heavy-chain region (I(H)-C(H)). Following infection, can participate in CD8(+) dendritic cell differentiation via interaction with IRF4 and IRF8 to mediate cooperative gene activation. Regulates effector CD8(+) T-cell differentiation by regulating expression of SIRT1. Following DNA damage, part of a differentiation checkpoint that limits self-renewal of hematopoietic stem cells (HSCs): up-regulated by STAT3, leading to differentiation of HSCs, thereby restricting self-renewal of HSCs (By similarity).

> Gene Ontology
 
Biological Process GO:0001562 response to protozoan
GO:0001773 myeloid dendritic cell activation
GO:0002200 somatic diversification of immune receptors
GO:0002204 somatic recombination of immunoglobulin genes involved in immune response
GO:0002208 somatic diversification of immunoglobulins involved in immune response
GO:0002244 hematopoietic progenitor cell differentiation
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002287 alpha-beta T cell activation involved in immune response
GO:0002292 T cell differentiation involved in immune response
GO:0002293 alpha-beta T cell differentiation involved in immune response
GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response
GO:0002295 T-helper cell lineage commitment
GO:0002312 B cell activation involved in immune response
GO:0002320 lymphoid progenitor cell differentiation
GO:0002360 T cell lineage commitment
GO:0002363 alpha-beta T cell lineage commitment
GO:0002366 leukocyte activation involved in immune response
GO:0002377 immunoglobulin production
GO:0002381 immunoglobulin production involved in immunoglobulin mediated immune response
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
GO:0002573 myeloid leukocyte differentiation
GO:0006310 DNA recombination
GO:0007159 leukocyte cell-cell adhesion
GO:0016064 immunoglobulin mediated immune response
GO:0016444 somatic cell DNA recombination
GO:0016445 somatic diversification of immunoglobulins
GO:0016447 somatic recombination of immunoglobulin gene segments
GO:0019724 B cell mediated immunity
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030217 T cell differentiation
GO:0030330 DNA damage response, signal transduction by p53 class mediator
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0042092 type 2 immune response
GO:0042093 T-helper cell differentiation
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042770 signal transduction in response to DNA damage
GO:0042832 defense response to protozoan
GO:0043011 myeloid dendritic cell differentiation
GO:0043367 CD4-positive, alpha-beta T cell differentiation
GO:0043368 positive T cell selection
GO:0043369 CD4-positive or CD8-positive, alpha-beta T cell lineage commitment
GO:0043373 CD4-positive, alpha-beta T cell lineage commitment
GO:0045058 T cell selection
GO:0045064 T-helper 2 cell differentiation
GO:0045165 cell fate commitment
GO:0045190 isotype switching
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0048863 stem cell differentiation
GO:0060218 hematopoietic stem cell differentiation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0072331 signal transduction by p53 class mediator
GO:0072538 T-helper 17 type immune response
GO:0072539 T-helper 17 cell differentiation
GO:0072540 T-helper 17 cell lineage commitment
GO:0097028 dendritic cell differentiation
GO:0098542 defense response to other organism
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-449147: Signaling by Interleukins
Summary
SymbolBATF
Namebasic leucine zipper transcription factor, ATF-like
Aliases SFA-2; BATF1; activating transcription factor B; SF-HT-activated gene 2; B-ATF1; SFA2; B-cell-activating tra ......
Chromosomal Location14q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BATF and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between BATF and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28494239Endemic Burkitt LymphomaInhibit immunityOur systematic approach uncovered key mechanisms by which EBV oncoproteins activate the PI3K/AKT pathway and evade tumor suppressor responses. LMP1-induced cFLIP was found to be critical for LCL defense against TNFα-mediated programmed cell death, whereas EBV-induced BATF/IRF4 were critical for BIM suppression and MYC induction in LCLs.
Summary
SymbolBATF
Namebasic leucine zipper transcription factor, ATF-like
Aliases SFA-2; BATF1; activating transcription factor B; SF-HT-activated gene 2; B-ATF1; SFA2; B-cell-activating tra ......
Chromosomal Location14q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BATF in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBATF
Namebasic leucine zipper transcription factor, ATF-like
Aliases SFA-2; BATF1; activating transcription factor B; SF-HT-activated gene 2; B-ATF1; SFA2; B-cell-activating tra ......
Chromosomal Location14q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BATF in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2150.695
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.7350.665
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9030.461
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6480.213
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1920.872
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.2130.329
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6090.276
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8450.355
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4030.673
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.0490.114
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3630.503
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0650.64
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BATF in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolBATF
Namebasic leucine zipper transcription factor, ATF-like
Aliases SFA-2; BATF1; activating transcription factor B; SF-HT-activated gene 2; B-ATF1; SFA2; B-cell-activating tra ......
Chromosomal Location14q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BATF. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBATF
Namebasic leucine zipper transcription factor, ATF-like
Aliases SFA-2; BATF1; activating transcription factor B; SF-HT-activated gene 2; B-ATF1; SFA2; B-cell-activating tra ......
Chromosomal Location14q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BATF. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BATF.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBATF
Namebasic leucine zipper transcription factor, ATF-like
Aliases SFA-2; BATF1; activating transcription factor B; SF-HT-activated gene 2; B-ATF1; SFA2; B-cell-activating tra ......
Chromosomal Location14q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BATF. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBATF
Namebasic leucine zipper transcription factor, ATF-like
Aliases SFA-2; BATF1; activating transcription factor B; SF-HT-activated gene 2; B-ATF1; SFA2; B-cell-activating tra ......
Chromosomal Location14q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BATF expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBATF
Namebasic leucine zipper transcription factor, ATF-like
Aliases SFA-2; BATF1; activating transcription factor B; SF-HT-activated gene 2; B-ATF1; SFA2; B-cell-activating tra ......
Chromosomal Location14q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BATF and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBATF
Namebasic leucine zipper transcription factor, ATF-like
Aliases SFA-2; BATF1; activating transcription factor B; SF-HT-activated gene 2; B-ATF1; SFA2; B-cell-activating tra ......
Chromosomal Location14q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BATF collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.